{"id":827921,"date":"2025-03-20T07:34:03","date_gmt":"2025-03-20T11:34:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-introduces-reyobiq-fda-accepted-proprietary-name-for-lead-drug-candidate\/"},"modified":"2025-03-20T07:34:03","modified_gmt":"2025-03-20T11:34:03","slug":"plus-therapeutics-introduces-reyobiq-fda-accepted-proprietary-name-for-lead-drug-candidate","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-introduces-reyobiq-fda-accepted-proprietary-name-for-lead-drug-candidate\/","title":{"rendered":"Plus Therapeutics Introduces REYOBIQ\u2122, FDA-Accepted Proprietary Name for Lead Drug Candidate"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>\u00a0REYOBIQ\u2122 (rhenium Re<sup>186<\/sup> obisbemeda) continues to be under clinical investigation for Leptomeningeal Metastases (LM) and Recurrent Glioblastoma (GBM) <\/em>\n      <\/p>\n<p align=\"justify\">HOUSTON, March  20, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=i-qb9IbAZS8Tq3Q3fWYuawClT0FgGs6UaC87gapHpDqEA6kqNe5NVbM-jQw2EwvXRiL7K4aZUkqpoUX39IM6IzcNUyP3jBpWnUyhiTQ2bzuEzSjQwcYdjFMvAotC9LsN\" rel=\"nofollow\" target=\"_blank\">Plus Therapeutics, Inc.<\/a> (Nasdaq:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=n0c6yyKq9X9xJ4J7kvSaKoU-7uph0EpxvGwDp84RynjEBb8mYbcsYznd6puBC8wYg1iESKsohOA06z5v5Fwvrg==\" rel=\"nofollow\" target=\"_blank\">PSTV<\/a>) (the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces\u00a0the U.S. Food and Drug Administration (FDA) has conditionally accepted the Company\u2019s new proprietary name, REYOBIQ\u2122, for its lead therapeutic candidate. A request for proprietary name review for REYOBIQ\u2122 must be submitted once the marketing application (NDA) is submitted. All communications regarding the USAN-adopted and INN-recommended rhenium Re<sup>186<\/sup> obisbemeda generic name will now utilize the proprietary name REYOBIQ\u2122.<\/p>\n<p align=\"justify\">&#8220;Branding is an important part of preparing for commercialization, and the establishment of the REYOBIQ\u2122 brand will enable investigators, investors, and potential patients to connect with our rhenium-based radiotherapeutic beyond its chemical identity,&#8221; said Russ Havranek, Plus Therapeutics VP of Corporate Strategy and New Product Planning. &#8220;We are looking forward to building familiarity with the new REYOBIQ\u2122 name and logo, as we believe it will foster stronger stakeholder engagement and reinforce the promising progress we are making in developing targeted radiotherapeutics for LM and GBM.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About REYOBIQ<\/strong>\u2122 <strong>(rhenium Re<\/strong><sup><strong>186<\/strong><\/sup><strong> obisbemeda)<br \/><\/strong>REYOBIQ\u2122 (rhenium Re<sup>186<\/sup> obisbemeda) is a novel injectable radiotherapy specifically formulated to deliver direct targeted high dose radiation in CNS tumors in a safe, effective, and convenient manner to optimize patient outcomes. REYOBIQ\u2122 has the potential to reduce off target risks and improve outcomes for CNS cancer patients, versus currently approved therapies, with a more targeted and potent radiation dose. Rhenium-186 is an ideal radioisotope for CNS therapeutic applications due to its short half-life, beta energy for destroying cancerous tissue, and gamma energy for real-time imaging. REYOBIQ\u2122 is being evaluated for the treatment of recurrent glioblastoma and leptomeningeal metastases in the ReSPECT-GBM and ReSPECT-LM clinical trials. ReSPECT-GBM is supported by an award from the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), and ReSPECT-LM is funded by a three-year $17.6M grant by the Cancer Prevention &amp; Research Institute of Texas (CPRIT).<\/p>\n<p align=\"justify\">\n        <strong>About Plus Therapeutics<\/strong><br \/>\n        <br \/>Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit https:\/\/plustherapeutics.com\/.<\/p>\n<p>\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>Jules Abraham<br \/>Managing Director, Communications<br \/>CORE IR<br \/>Julesa@coreir.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjY5MCM2ODEyNTM0IzIwMDQ4MDU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MmQ4YWZlMmQtMjRmOC00ZWYzLTk0ZjAtNTBjZDNmZDlmZTQwLTEwMTYzNzgtMjAyNS0wMy0yMC1lbg==\/tiny\/Plus-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u00a0REYOBIQ\u2122 (rhenium Re186 obisbemeda) continues to be under clinical investigation for Leptomeningeal Metastases (LM) and Recurrent Glioblastoma (GBM) HOUSTON, March 20, 2025 (GLOBE NEWSWIRE) &#8212; Plus Therapeutics, Inc. (Nasdaq:\u00a0PSTV) (the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces\u00a0the U.S. Food and Drug Administration (FDA) has conditionally accepted the Company\u2019s new proprietary name, REYOBIQ\u2122, for its lead therapeutic candidate. A request for proprietary name review for REYOBIQ\u2122 must be submitted once the marketing application (NDA) is submitted. All communications regarding the USAN-adopted and INN-recommended rhenium Re186 obisbemeda generic name will now utilize the proprietary name REYOBIQ\u2122. &#8220;Branding is an important part of preparing for commercialization, and the establishment of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-introduces-reyobiq-fda-accepted-proprietary-name-for-lead-drug-candidate\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Plus Therapeutics Introduces REYOBIQ\u2122, FDA-Accepted Proprietary Name for Lead Drug Candidate&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-827921","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Plus Therapeutics Introduces REYOBIQ\u2122, FDA-Accepted Proprietary Name for Lead Drug Candidate - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-introduces-reyobiq-fda-accepted-proprietary-name-for-lead-drug-candidate\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Plus Therapeutics Introduces REYOBIQ\u2122, FDA-Accepted Proprietary Name for Lead Drug Candidate - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u00a0REYOBIQ\u2122 (rhenium Re186 obisbemeda) continues to be under clinical investigation for Leptomeningeal Metastases (LM) and Recurrent Glioblastoma (GBM) HOUSTON, March 20, 2025 (GLOBE NEWSWIRE) &#8212; Plus Therapeutics, Inc. (Nasdaq:\u00a0PSTV) (the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces\u00a0the U.S. Food and Drug Administration (FDA) has conditionally accepted the Company\u2019s new proprietary name, REYOBIQ\u2122, for its lead therapeutic candidate. A request for proprietary name review for REYOBIQ\u2122 must be submitted once the marketing application (NDA) is submitted. All communications regarding the USAN-adopted and INN-recommended rhenium Re186 obisbemeda generic name will now utilize the proprietary name REYOBIQ\u2122. &#8220;Branding is an important part of preparing for commercialization, and the establishment of &hellip; Continue reading &quot;Plus Therapeutics Introduces REYOBIQ\u2122, FDA-Accepted Proprietary Name for Lead Drug Candidate&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-introduces-reyobiq-fda-accepted-proprietary-name-for-lead-drug-candidate\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-20T11:34:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjY5MCM2ODEyNTM0IzIwMDQ4MDU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-introduces-reyobiq-fda-accepted-proprietary-name-for-lead-drug-candidate\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-introduces-reyobiq-fda-accepted-proprietary-name-for-lead-drug-candidate\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Plus Therapeutics Introduces REYOBIQ\u2122, FDA-Accepted Proprietary Name for Lead Drug Candidate\",\"datePublished\":\"2025-03-20T11:34:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-introduces-reyobiq-fda-accepted-proprietary-name-for-lead-drug-candidate\\\/\"},\"wordCount\":458,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-introduces-reyobiq-fda-accepted-proprietary-name-for-lead-drug-candidate\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NjY5MCM2ODEyNTM0IzIwMDQ4MDU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-introduces-reyobiq-fda-accepted-proprietary-name-for-lead-drug-candidate\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-introduces-reyobiq-fda-accepted-proprietary-name-for-lead-drug-candidate\\\/\",\"name\":\"Plus Therapeutics Introduces REYOBIQ\u2122, FDA-Accepted Proprietary Name for Lead Drug Candidate - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-introduces-reyobiq-fda-accepted-proprietary-name-for-lead-drug-candidate\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-introduces-reyobiq-fda-accepted-proprietary-name-for-lead-drug-candidate\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NjY5MCM2ODEyNTM0IzIwMDQ4MDU=\",\"datePublished\":\"2025-03-20T11:34:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-introduces-reyobiq-fda-accepted-proprietary-name-for-lead-drug-candidate\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-introduces-reyobiq-fda-accepted-proprietary-name-for-lead-drug-candidate\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-introduces-reyobiq-fda-accepted-proprietary-name-for-lead-drug-candidate\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NjY5MCM2ODEyNTM0IzIwMDQ4MDU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NjY5MCM2ODEyNTM0IzIwMDQ4MDU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-introduces-reyobiq-fda-accepted-proprietary-name-for-lead-drug-candidate\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Plus Therapeutics Introduces REYOBIQ\u2122, FDA-Accepted Proprietary Name for Lead Drug Candidate\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Plus Therapeutics Introduces REYOBIQ\u2122, FDA-Accepted Proprietary Name for Lead Drug Candidate - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-introduces-reyobiq-fda-accepted-proprietary-name-for-lead-drug-candidate\/","og_locale":"en_US","og_type":"article","og_title":"Plus Therapeutics Introduces REYOBIQ\u2122, FDA-Accepted Proprietary Name for Lead Drug Candidate - Market Newsdesk","og_description":"\u00a0REYOBIQ\u2122 (rhenium Re186 obisbemeda) continues to be under clinical investigation for Leptomeningeal Metastases (LM) and Recurrent Glioblastoma (GBM) HOUSTON, March 20, 2025 (GLOBE NEWSWIRE) &#8212; Plus Therapeutics, Inc. (Nasdaq:\u00a0PSTV) (the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces\u00a0the U.S. Food and Drug Administration (FDA) has conditionally accepted the Company\u2019s new proprietary name, REYOBIQ\u2122, for its lead therapeutic candidate. A request for proprietary name review for REYOBIQ\u2122 must be submitted once the marketing application (NDA) is submitted. All communications regarding the USAN-adopted and INN-recommended rhenium Re186 obisbemeda generic name will now utilize the proprietary name REYOBIQ\u2122. &#8220;Branding is an important part of preparing for commercialization, and the establishment of &hellip; Continue reading \"Plus Therapeutics Introduces REYOBIQ\u2122, FDA-Accepted Proprietary Name for Lead Drug Candidate\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-introduces-reyobiq-fda-accepted-proprietary-name-for-lead-drug-candidate\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-20T11:34:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjY5MCM2ODEyNTM0IzIwMDQ4MDU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-introduces-reyobiq-fda-accepted-proprietary-name-for-lead-drug-candidate\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-introduces-reyobiq-fda-accepted-proprietary-name-for-lead-drug-candidate\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Plus Therapeutics Introduces REYOBIQ\u2122, FDA-Accepted Proprietary Name for Lead Drug Candidate","datePublished":"2025-03-20T11:34:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-introduces-reyobiq-fda-accepted-proprietary-name-for-lead-drug-candidate\/"},"wordCount":458,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-introduces-reyobiq-fda-accepted-proprietary-name-for-lead-drug-candidate\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjY5MCM2ODEyNTM0IzIwMDQ4MDU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-introduces-reyobiq-fda-accepted-proprietary-name-for-lead-drug-candidate\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-introduces-reyobiq-fda-accepted-proprietary-name-for-lead-drug-candidate\/","name":"Plus Therapeutics Introduces REYOBIQ\u2122, FDA-Accepted Proprietary Name for Lead Drug Candidate - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-introduces-reyobiq-fda-accepted-proprietary-name-for-lead-drug-candidate\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-introduces-reyobiq-fda-accepted-proprietary-name-for-lead-drug-candidate\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjY5MCM2ODEyNTM0IzIwMDQ4MDU=","datePublished":"2025-03-20T11:34:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-introduces-reyobiq-fda-accepted-proprietary-name-for-lead-drug-candidate\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-introduces-reyobiq-fda-accepted-proprietary-name-for-lead-drug-candidate\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-introduces-reyobiq-fda-accepted-proprietary-name-for-lead-drug-candidate\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjY5MCM2ODEyNTM0IzIwMDQ4MDU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjY5MCM2ODEyNTM0IzIwMDQ4MDU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-introduces-reyobiq-fda-accepted-proprietary-name-for-lead-drug-candidate\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Plus Therapeutics Introduces REYOBIQ\u2122, FDA-Accepted Proprietary Name for Lead Drug Candidate"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827921","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=827921"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827921\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=827921"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=827921"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=827921"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}